In my opinion, a medical cannabis company should always utilise all the available capital and resources on its core business (i.e. MM) and the participation in any "new project" implies a change of business direction, which always look like a red flag to me.
Furthermore, most people believe this COVID-19 virus is not going to last long, most likely last less than an year. So a big question for the company will be whether the change of business direction under current market environment, will be sustainable for the company in long term?
Ann: Trading Halt, page-44
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
0.030(9.38%) |
Mkt cap ! $16.94M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 35.0¢ | 32.0¢ | $3.361K | 9.732K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16739 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 8746 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| RGT (ASX) Chart |